![HelixTalk - Rosalind Franklin University's College of Pharmacy Podcast artwork](https://is1-ssl.mzstatic.com/image/thumb/Podcasts113/v4/89/d0/1c/89d01c4e-f16a-b250-50ec-8e5cfee21d11/mza_3581079248703134654.png/100x100bb.jpg)
153 - Buy One Get One Free: Learning All about the Dual Acting GIP and GLP-1 Receptor Agonist
HelixTalk - Rosalind Franklin University's College of Pharmacy Podcast
English - September 06, 2022 10:00 - 49 minutes - 46.8 MB - ★★★★★ - 549 ratingsMedicine Health & Fitness Education drugs medicine rosalindfranklin medications pharmacist pharmacy pharmd rfums Homepage Download Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed
Previous Episode: 152 - Strain-ger Things: Pneumococcal Vaccine Updates
In this episode, we will discuss mechanism, pharmacokinetics, efficacy, safety, and possible place in therapy for tirzepatide (Mounjaro), a new treatment for type 2 diabetes.
Key Concepts
Tirzepatide is a novel GIP and GLP-1 receptor agonist resulting in glucose-dependent secretion of insulin and a decrease in glucagon secretion. This medication was FDA approved in May 2022 for the treatment of type 2 diabetes as an adjunct to diet and exercise. It is available as a long-acting once weekly pen injection to be administered subcutaneously. Current efficacy data exist from a 40-week trial which showed that tirzepatide was superior to semaglutide in A1c reduction and weight loss. The most common adverse effects of tirzepatide include GI concerns such as nausea, vomiting, and diarrhea as well as hypoglycemia.References
Frias JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med. 2021;385:503-515. https://www.nejm.org/doi/full/10.1056/NEJMoa2107519 Mounjaro. Package insert. Elli Lilly and Company. 2022.